First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
_256_384.jpg)
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Subscribe To Our Newsletter & Stay Updated
